Association between serum soluble receptor for advanced glycation end-products (RAGE) deficiency and severity of clinicopathologic evidence of canine chronic inflammatory enteropathy.

Abstract

Innate immunity plays a central role in the pathogenesis of chronic inflammatory enteropathies (CIE) in dogs, and further evaluation of the innate immune receptor for advanced glycation end-products (RAGE) is warranted. We measured serum concentrations of decoy receptor soluble RAGE (sRAGE) in 102 dogs diagnosed with CIE, and evaluated relationships with clinical disease severity, histologic lesion severity, concentrations of serum C-reactive protein (CRP), and serum and fecal calprotectin, S100A12, and alpha-proteinase inhibitor (&#x3b1;PI). Serum sRAGE levels were not associated with clinical disease activity, serum CRP, serum and fecal &#x3b1;PI, calprotectin, or S100A12 concentrations. Microscopic lesions in the duodenum were more severe in dogs with serum sRAGE concentration &#x2264;&#x2009;340&#x2009;ng/L (&#x2009;=&#x2009;0.013). Serum sRAGE levels were weakly and inversely correlated with the severity of lymphoplasmacytic infiltration in the gastric antrum and duodenum, and with crypt dilation and the neutrophilic infiltrate in the duodenum, in univariate analysis (all&#x2009;<&#x2009;0.05), but none of the correlations remained statistically significant after correction for multiple comparisons. Our study confirms that CIE in dogs is associated with decreased serum sRAGE concentrations, suggesting a dysregulated sRAGE/RAGE axis.